Osajin (CID 95168)

Cell experiment:

NPC cells are seeded in 96-well plates (5000/well) and allowed to adhere for 24 h. The medium is then substituted by a fresh one containing different concentrations (0.01–10 µM) of osajin for another 24 h. For the time-course assay, the incubation times with 5 µM of osajin are 6, 12, 24, 36 and 48 h. After incubation, 10 µl of 5 mg/ml of MTT is added to each well and incubated for 4 h at 37°C. Cell viability is determined using the MTT-based assay[1].

Animal experiment:

Rats[1]The Wistar rats are divided into four groups. The first treatment group receives osajin (5 mg/kg/day in 0.5% Avicel); the second treatment group receives pomiferin (5 mg/kg/day in 0.5% Avicel); the placebo group receives only 0.5 Avicel; the last is an untreated control group. Biochemical indicator of oxidative damage-lipid peroxidation product malondialdehyde, antioxidant enzymes-superoxide dismutase, glutathione peroxidase, total antioxidant activity in serum and myocardium are evaluated. The effect of osajin and pomiferin on cardiac function, left ventricular end-diastolic pressure, left ventricular pressure and peak positive +dP/dt ischemia and reperfusion, also is examined[1].

References:

[1]. Huang TT, et al. Activation of multiple apoptotic pathways in human nasopharyngeal carcinoma cells by the prenylated isoflavone, osajin. PLoS One. 2011 Apr 12;6(4):e18308.
[2]. Son IH, et al. Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4753-5.
[3]. Florian T, et al. Effects of prenylated isoflavones osajin and pomiferin in premedication on heart ischemia-reperfusion. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):93-100.